• RSL3, PARP1, and Ferroptosis–Apoptosis Crosstalk

  2026-10-04

  The 2025 study by Chen and colleagues identifies PARP1 as a mechanistic bridge between RSL3-induced ferroptosis and apoptosis, describing both caspase-dependent PARP1 cleavage and reduced full-length PARP1 production. Its findings extend the interpretation of RSL3 beyond GPX4 inhibition and suggest relevance to PARP inhibitor-resistant tumor models, while remaining dependent on the study’s cancer-cell and xenograft systems.

• Sodium Pyruvate in Animal Pharming Research

  2026-10-03

  Sodium pyruvate is more than a routine cell-culture supplement: its metabolic effects can shape how recombinant-protein studies are interpreted. This article examines its biochemical context alongside the targeted rabbit pharming strategy reported by Song et al., separating demonstrated findings from plausible but untested connections.

• Sodium Pyruvate and the Next Pharming Platform

  2026-10-02

  A targeted rabbit pharming study shows how promoter choice, precise genome editing, and inherited alleles can move recombinant protein production beyond the variability of conventional transgenesis. This article translates those findings into a strategic framework for researchers evaluating metabolic controls, assay design, and the translational role of Sodium pyruvate.

• SW033291: A 15-PGDH Assay-to-Repair Framework

  2026-10-01

  SW033291 is a potent 15-PGDH inhibitor for connecting prostaglandin E2 elevation with tissue repair biology. This article develops an assay-to-phenotype framework for interpreting muscle regeneration, hematopoiesis, and target-engagement data without confusing compound-specific evidence with broader 15-PGDH biology.

• Spatial PD-L1–IL-6 Crosstalk in PSC

  2026-10-01

  Orlandi and colleagues use spatial proteomics and cell-cell cross-talk analysis to examine how PD-L1 and IL-6 are organized at the epithelial–immune interface in human primary sclerosing cholangitis. The study’s main contribution is a spatial framework for interpreting coupled immune-checkpoint and inflammatory signals, while its findings also define important limits for causal and therapeutic extrapolation.

• gamma-Glu-Cys: Practical Assay and Workflow Guide

  2026-09-30

  gamma-Glu-Cys provides a defined, soluble intermediate for glutathione synthetase assays, glutathione metabolism research, and carefully controlled γ-glutamyl peptide experiments. This guide translates recent Bacillus fermentation findings into practical substrate controls, workflow choices, and troubleshooting steps while keeping product specifications separate from experimental recommendations.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-09-30

  The reference study combines genetic ablation, inducible mouse modeling, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its findings position FGFR3 inhibition, including treatment with NVP-BGJ398, as a mechanistically supported strategy for improving chondrocyte differentiation and skeletal architecture, while leaving important translational questions unresolved.

• DAPI Solution (1 mg/mL): Nuclear Assay Guide

  2026-09-29

  DAPI, or 4',6-Diamidino-2-Phenylindole, is a DNA-binding fluorescent stain for nuclear visualization, fixed-cell imaging, and selected flow cytometry workflows. The K2401 DMSO stock supports reproducible assay setup, but DAPI signal alone cannot establish apoptosis, viability, or exosome mechanism.

• Bay 11-7085: Mapping NF-κB–Apoptosis Coupling

  2026-09-29

  Bay 11-7085 is an NF-κB activation inhibitor that can connect inflammatory signaling with cell-cycle control and apoptosis. This guide develops a pathway-mapping strategy informed by endoplasmic-reticulum-stress research, while clarifying what the probe can—and cannot—prove in cellular and animal models.

• PBA-Targeted PAD4 Inhibitors and Tumor NETs

  2026-09-28

  This study develops phenylboronic acid (PBA)-modified PAD4 inhibitors designed to concentrate activity in tumors while suppressing the PAD4–H3cit–NETs pathway in neutrophils. The lead compound 5i inhibited tumor growth and lung metastasis in mouse models, providing a targeting strategy that links tumor-cell recognition with modulation of the tumor immune microenvironment.

• A40926 Biosynthesis and Dalbavancin Pathway Engineering

  2026-09-28

  Sosio and Donadio’s review connects characterization of the A40926 biosynthetic gene cluster with pathway engineering in its Nonomuraea producer, showing how targeted gene inactivation can generate new glycopeptide derivatives. The work also highlights biosynthetic differences between teicoplanin- and vancomycin-family antibiotics, offering a framework for interpreting A40926 as both a complex natural product and a dalbavancin precursor.

• Tunicamycin: From ER Stress to Translational Insight

  2026-09-27

  Tunicamycin offers researchers a direct way to perturb protein N-glycosylation and examine how ER stress reshapes cellular responses. This article connects its use as an N-glycosylation inhibitor with emerging evidence on QRICH1, HMGB1, and HBV-associated liver fibrosis—while distinguishing experimental opportunity from translational proof.

• 10074-G5 Workflows for c-Myc Cancer Research

  2026-09-26

  Use 10074-G5 to test whether c-Myc/Max signaling helps sustain aggressive cancer-cell phenotypes, including the EMT and motility changes linked to miR-196a in esophageal adenocarcinoma. This guide combines practical dose-finding and assay controls with clear limits on what the existing evidence establishes.

• SIRT1 Links Vascular Activity to Aged Bone Repair

  2026-09-25

  Liu et al. report that SIRT1 supports endothelial activity and osteogenic differentiation in experimental models of skeletal aging, with β-catenin–Wnt signaling implicated as a downstream mediator. Pharmacological SIRT1 activation also improved regeneration in aged femoral and mandibular bone defects, providing a preclinical rationale for studying coordinated vascular and bone-cell responses in repair.

• Cytosine Base Editing: Fidelity Before Translation

  2026-09-25

  Cytosine base editing offers a precise route to targeted nucleotide changes, but editing efficiency alone is not a sufficient translational endpoint. Evidence from mouse embryos shows why editor-specific, genome-wide validation should accompany guide optimization and functional testing. This article connects that evidence to practical research decisions for EZ Cap™ CBEmax mRNA (m1Ψ), while distinguishing published findings from product-specific performance claims.

8645 records 3/577 page Previous Next 12345 下5页 Last page